SGX 001
Alternative Names: SGX-001Latest Information Update: 10 Oct 2024
Price :
$50 *
At a glance
- Originator Somagenetix
- Class Gene therapies
- Mechanism of Action Gene transference; Neutrophil cytosolic factor 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chronic granulomatous disease
Most Recent Events
- 08 Oct 2024 SGX 001 is available for licensing as of 08 Oct 2024. https://www.somagenetix.com/ (Somagenetix AG website, October 2024)
- 08 Oct 2024 Preclinical trials in Chronic granulomatous disease in Switzerland (Parenteral), prior to October 2024
- 08 Oct 2024 Somagenetix AG plans a clinical trial for SGX 001 in Chronic granulomatous disease in 2026